

and B 1/2/2 Ges

Attorney Docket No. 012712-256

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of)
Darrell R. ANDERSON et al	
Serial No. 08/746,361) Group Art Unit: 1806
Filed: November 8, 1996) Examiner: P. Gambel)
For: IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS	RECEIVED NOV 6 5 1997 GROUP 1800
REPLY AND AMENDME	NTS PURSUANT TO

REPLY AND AMENDMENTS PURSUANT TO 37 C.F.R. §§1.111, 1.115 AND 1.119

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

In response to the Office Action dated April 11, 1997, kindly amend the above-identified application as follows:

IN THE CLAIMS:

Kindly cancel Claims 1 through 28, without prejudice or disclaimer, and substitute the following claims therefor:

- --29. A monoclonal antibody which specifically binds to human B7.1 antigen (CD80), which antibody inhibits the binding of B7.1 antigen to CD28 but which antibody does not inhibit the binding of B7.1 antigen to CTLA-4.
- 30. The antibody of Claim 29, which inhibits the production of IL-2 by T-lymphocytes.